Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
By G. Lau, T. Piratvisuth, K. Luo, P. Marcellin, Satawat Thongsawat, G. Cooksley, E. Gane, M. Fried, W. Chow, S. Paik and 5 more. New England Journal of Medicine, 2005
1,387 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/046135b587c30005cd4393c29f9ac59a5a6448fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012, neutral): “post-treatment [69].”
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “Significantly better response in genotype B infected patients (31% vs. 17.5% of genotype C infected; P \ 0.05) was observed in earlier 6-month PegIFN-a2a trial [46] but not in the recent 12-month trial [ 47 ].”
- Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008, neutral): “treat analysis¶ 134/176 (76) 12/90 ( 13 ) 13 ) 30 (14)”
- Interferons at age 50: past, current and future impact on biomedicine (2007, background): “IFNα2 (RoferonA, Hoffmann LaRoche; IntronA, Schering-Plough), now usually in the form of a longacting pegylated version, has been widely used to treat HbeAgpositive Hbv infections 158 .”
- EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, neutral): “1) [38] [39] [40] [41] [42] [43] [44].”
- Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg-IFN; Tables 1 and 2)((6-16)) (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B).”